Eur Cardiol. A shift in the routine prescribing of statin therapy to every-other-day would have important implications. HHS Am J Cardiol 2003;92:152-160. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. 5 to 20 mg) in patients with a previous statin intolerance Am J Cardiol, 103 (3) (2009), pp. The statins are generally taken once daily and are available in generic forms. Get the latest public health information from CDC: https://www.coronavirus.gov. Conclusion: You must have JavaScript enabled to enjoy a limited number of articles over the next 360 days. Published data have demonstrated that instead of administering rosuvastatin on a daily basis, alternative dosing schedules (every other day, three times a week, and twice a week) for patients with previous adverse events, presumably secondary to statin therapy, have improved patient tolerability and at the same time are capable of significantly lowering total serum cholesterol and low-density lipoprotein cholesterol (LDL-C).1-3 These results were probably possible because of rosuvastatin's long half-life (approximately 19 hours)4 and, because the LDL-C reduction was significant5 in these studies, it has been suggested that rosuvastatin might be an attractive statin agent for a weekly dosing schedule. Backes JM, et al. ReliasMedia_AR@reliasmedia.com, Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales, For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com, Design, CMS, Hosting & Web Development :: ePublishing, New contraceptives widen choices, but the Pill still is a top selection, Statin Use Is Associated With a Lower Risk of Community-acquired. A significant difference in the mean percentage change in LDL from baseline for rosuvastatin vs. placebo was identified (12.2% reduction vs. 0.4% reduction, respectively; P = .002). Objective: Synopsis: Once-a-week rosuvastatin therapy was well tolerated in patients with a history of adverse events to one or more statins and led to significantly improved lipoprotein changes. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? The once-a-week schedule was tolerated by 74% of the patients with doses ranging from 2.5 to 20 mg once weekly. May be taken at any time of the day (morning or night); however, it is best to be consistent with the time you take your tablets. The specific dosage used for each patient was based primarily on each patient's prior history of statin use and the severity of the adverse events that they developed. It is important to recognize that the retrospective observational study reported by Ruisinger was performed in a very small group of patients (n = 50) and was not placebo-controlled. Please click here to continue without javascript.. Is an Even Safer Combined Oral Contraceptive Pill Available? Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Am J Cardiol 2007;99:291. Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Nearly all patients (92%) were also taking other lipid-altering agents such as ezetimide, nicotinic acid, fibrates, bile acid sequestrants, and/or omega-3 fatty acids. Results: A significant difference in the mean percentage change in LDL from baseline for rosuvastatin … Ruisinger and her colleagues mounted a study in an attempt to test the efficacy of once-a-week rosuvastatin on the lipid profile in patients with previous adverse events presumably secondary to a statin drug. Weekly dosing has the potential to lower costs and increase convenience while maintaining a similar effect on lipids. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Gadarla M, et al. Once-weekly low-dose rosuvastatin is an effective and well-tolerated lipid-lowering therapy option for patients not at LDL goal and previously unable to tolerate statins because of a history of myalgias. Background: Statin Use and Cognitive Effects: Not a Brain Drain. PLoS Curr. A prospective trial of once-a-week rosuvastatin dosing in individuals with a history of myalgias on statin therapy achieved a >12% lowering of LDL-C … Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. “It’s important to note that atorvastatin and rosuvastatin really are the workhorses of cardiology and statins … Once-a-week rosuvastatin (2. 393-394 Article Download PDF View Record in Scopus Google Scholar The average dosage used was 9.5 mg/week. Many patients who could benefit from hydroxymethylglutaryl coenzyme-A reductase inhibitors (statins) are unable to take statins because of myalgias while taking previous statin therapy. Clipboard, Search History, and several other advanced features are temporarily unavailable. The primary efficacy outcome was the difference in the mean percentage change in LDL from baseline between rosuvastatin and placebo. 2008 Mar;42(3):341-6. doi: 10.1345/aph.1K604. Patients with lipid levels measured 1-3 days and 4-7 days after receiving their last rosuvastatin dose had similar mean LDL-C reductions. Patients tolerating the once-a-week dosing regimen experienced a 17% reduction in total cholesterol, a 23% reduction in LDL-C, a 12% reduction in triglycerides, and a 5% increase in high-density lipoprotein cholesterol (all significant, P < 0.001) during a mean follow-up period of 4 months. Atorvastatin is a potent antihyperlipidemic but is quite expensive, costing up to $700 for a 1-year supply of 10-mg tablets in retail pharmacies. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000. There are exceptions to taking these nutrients so ask your doctor (yes, the same one that gave you the statin.) Am J Cardiol 2009;103:393-394. Am J Cardiovasc Drugs. NIH 1. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. In this randomized, double-blind, placebo-controlled crossover study we enrolled a total of 17 Clement J. Zablocki Veterans Affairs (VA) primary care patients with a diagnosis of hyperlipidemia and a history of myalgias on statin therapy who were not currently on a statin and not at LDL goal. Ferdinand KC, Davidson MH, Kelly MT, Setze CM. Two 8-week treatment phases consisted of rosuvastatin 5 mg once-weekly or matching placebo, with a dose titration to 10 mg once-weekly if not at LDL goal at week 4. Jones PH, et al; STELLAR Study Group. Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, Moriarty PM.